Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05460130
Other study ID # Study 1656
Secondary ID IN-US-987-6016
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date September 29, 2022
Est. completion date September 20, 2023

Study information

Verified date April 2023
Source University of Texas at Austin
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Highly-effective, pan-genotypic direct acting antivirals (DAAs) have made elimination of hepatitis C virus (HCV) a real possibility. A minority of the population infected with HCV has access to care or been prescribed such HCV treatment. Among people experiencing homelessness in the US, and seeking care at Health Care for the Homeless (HCH) clinics, prevalence is 31%, and 70% among people who experience homeless and inject drugs. In N. America, 55% of people who inject drugs (PWID) have HCV. Austin, TX has over 7,000 people experiencing homelessness with about 20% having a substance use disorder. Treatment of HCV via DAAs is feasible and effective in primary care settings, and is as effective as treatment by specialists. Among people with opioid use disorder receiving opioid agonist therapy it's both effective and cost-effective. Treatment in the primary care setting has also been shown to be feasible and effective for people experiencing homelessness, with supporting evidence of engaging and retaining people in care. Furthermore, a novel HCV treatment model, featuring a simplified HCV treatment algorithm for front-line health care providers (primary care physicians, Nurse Practitioners, Physicians Assistants), has now been published, to help increase capacity, scale-up treatment and achieve elimination. This study takes the foregoing new simplified approach one step further: Implementing this simplified algorithm for front-line health care providers in primary care settings caring for high-risk populations such as individuals experiencing homelessness and PWID. The novelty is providing treatment in diverse primary care settings, and targeting clinical sites serving high-risk populations, including people experiencing homelessness and PWID. Investigators use an implementation science approach to study the feasibility and effectiveness of the HCV treatment model in achieving HCV cure in high-risk populations. Investigators hypothesize that by training front-line health care providers on a simplified, low-barrier HCV treatment model and adapting it using a locally contextualized, protocol-driven approach, investigators will effectively scale up HCV treatment across multiple primary care clinical sites serving high-risk populations, yielding sustained virologic response at 12 weeks (SVR-12) in 75% of enrolled participants. Investigators predict theHCV treatment model to measure favorably across implementation process and outcome measures of reach, adoption, implementation, and maintenance.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 64
Est. completion date September 20, 2023
Est. primary completion date June 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult patients age 18 years and older. - Enrolled in care at one of CommunityCare's clinical sites participating in the study. - Laboratory diagnosis of HCV - Chronic hepatitis C infection Exclusion Criteria: - Have decompensated cirrhosis. - Have received hepatitis C treatment previously. - Had a liver transplant or actively on the transplant list awaiting a liver transplant. - Have resistant HCV virus - Infected with HIV - Infected with hepatitis B - Currently pregnant

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Simplified Hepatitis C Virus (HCV) Treatment Protocol
A simplified, low-barrier, locally contextualized, HCV treatment protocol delivered by trained front-line health care providers (primary care physicians and mid-level providers) serving hard-to-reach-populations.

Locations

Country Name City State
United States CommUnityCare Health Centers Austin Texas

Sponsors (1)

Lead Sponsor Collaborator
University of Texas at Austin

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Implementation Outcome: Reach Proportion of participants with chronic HCV enrolled in the study who are offered treatment Approximately one year from date of enrollment of first participant
Other Implementation Outcome: Adoption Proportion of clinical sites that adopt the HCV treatment protocol Approximately one year from date of enrollment of first participant
Other Implementation Outcome: Implementation Qualitative interviews to assess the extent to which the HCV treatment protocol was implemented as intended (fidelity) Approximately one year from date of enrollment of first participant
Other Implementation Outcome: Maintenance Qualitative interviews to assess the extent to which the HCV treatment protocol is sustained over time Approximately one year from date of enrollment of first participant
Primary Proportion of participants with chronic HCV infection enrolled in the study that achieve SVR-12 A sustained virological response is defined as an undetectable HCV RNA level 12 weeks after treatment completion. The measurement of SVR12 is assessed 12 weeks after completing treatment.
Secondary Clinical outcome: Time to treatment Time elapsed (in days) from being offered treatment to initiating treatment Approximately 10 months from time of enrollment
Secondary Clinical outcome: Complete HCV Treatment Proportion of participants enrolled in the study who complete HCV treatment Approximately 10 months from time of enrollment
Secondary Clinical outcome: Initiate HCV treatment Proportion of participants enrolled in the study who initiate HCV treatment Approximately 10 months from time of enrollment
See also
  Status Clinical Trial Phase
Completed NCT02487030 - Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection Phase 3
Completed NCT02220998 - Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection Phase 3
Terminated NCT01052090 - Safety and Efficacy Study in Hepatitis C Patients With PHN121 Phase 1/Phase 2
Completed NCT02537379 - Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection N/A
Recruiting NCT04156945 - Interventions to Curb Hepatitis C Reinfections Among Men Who Have Sex With Men N/A
Terminated NCT02510300 - A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials
Withdrawn NCT04309734 - Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects Phase 1/Phase 2
Active, not recruiting NCT04001608 - Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 1 Hepatitis C Virus Infection Patients Phase 3
Completed NCT04112303 - Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis Phase 3
Completed NCT02251717 - Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection Phase 2
Recruiting NCT05092074 - Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection
Recruiting NCT04005248 - Prevalence of HCV in HIV-negative MSM N/A
Completed NCT02249182 - Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection Phase 2
Completed NCT02939989 - Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study Phase 3
Completed NCT01718145 - A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects Phase 3
Completed NCT01482611 - A Study in Healthy Participants Investigating the Safety, Tolerability and Plasma Pharmacokinetics (PK) of Single Oral Doses of JNJ-47910382 Phase 1
Completed NCT00255177 - Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients Phase 2
Terminated NCT02600351 - Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies Phase 3
Completed NCT04980157 - CARES-HCV: Promoting Screening Uptake Among Diverse Baby Boomers
Completed NCT02350569 - Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting Phase 2